ASCVD Risk Hit Hard by COVID-19: A Lipidologist's View

Grace Halsey

Preventive cardiology and lipid specialist Seth J. Baum, MD, answers questions about the state of preventive cardiology in the midst of COVID-19.

Seth J. Baum, MD, discusses the "state of ASCVD risk assessment" in 2020 and highlights the potential COVID-19-related setbacks in cardiovascular health as healthy activity is limited, cooking and eating are ever-present in the media, and many individuals with chronic conditions, including hypertension, congestive heart failure, ACS, remain reluctant to make in-person appointments for follow-up.

Dr Baum is clinical professor, biomedical science, at the Florida Atlantic University Charles E. Schmidt College of Medicine; he is founder and chief medical officer of Excel Medical Clinical Trials, LLC, and past president of the American Society for Preventive Cardiology. He is in private practice i Boca Raton, FL, where he specializes in lipid disorders and cardiovascular disease prevention.